PHARMASSET, INC. Patent applications |
Patent application number | Title | Published |
20120232029 | 2',4'-SUBSTITUTED NUCLEOSIDES AS ANTIVIRAL AGENTS - Embodiments of the invention are to compounds, methods, and compositions for use in the treatment of viral infections. More specifically embodiments of the invention are 2′,4′-substituted nucleoside compounds useful for the treatment of viral infections, such as HIV, HCV, and HBV infections. | 09-13-2012 |
20120202794 | COMPOUNDS - Disclosed herein are compounds useful for treating a viral infection, such as HCV. | 08-09-2012 |
20120202766 | N4-ACYLCYTOSINE NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS - The present invention is directed to a method and composition of treating or preventing viral infections, in particular, human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infections, in human patients or other animal hosts, comprising the administration of N.sup.4-acyl-2′,3′-dideoxy-5-fluorocytidine or N.sup.4-acyl-2′,3′-didehyd-ro-2′,3′-dideoxy-5-fluorocytidine, and pharmaceutically acceptable salts, prodrugs, and other derivatives thereof. | 08-09-2012 |
20120142626 | COMPOUNDS - Disclosed herein are 2′-spiro-nucleosides and derivatives thereof useful for treating a subject infected by hepatitis C virus or dengue virus. | 06-07-2012 |
20120107278 | ABBREVIATED HCV THERAPY FOR HCV INFECTED PATIENTS WITH IL28B C/C GENOTYPE - Disclosed herein is a method for administering an abbreviated hepatitis C virus (HCV) treatment regimen for an HCV-infected, rs12979860 single nucleotide polymorphism (SNP) (C/C) patient, which comprises: administering to said patient an effective amount of each of a direct-acting antiviral, pegylated interferon alfa-2a, and ribavirin; wherein the abbreviated HCV treatment regimen is less than 48 weeks. Also disclosed herein is a method of detecting an rs12979860 single nucleotide polymorphism (SNP) in a hepatitis C virus (HCV) infected patient comprising: detecting the rs12979860 SNP of chromosome 19 in a biological sample from a patient, wherein an rs12979860 SNP C/C patient is administered an abbreviated treatment regimen with a direct-acting antiviral agent in combination with peginterferon alfa-2a and ribavirin; and wherein the abbreviated HCV treatment regimen is less than 48 weeks. | 05-03-2012 |
20110257122 | NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS - Disclosed herein are phosphoramidate prodrugs of nucleoside derivatives for the treatment of viral infections in mammals, which is a compound, its stereoisomer, salt (acid or basic addition salt), hydrate, solvate, or crystalline form thereof, represented by the following structure: | 10-20-2011 |
20110257121 | PURINE NUCLEOSIDE PHOSPHORAMIDATE - Disclosed herein is a compound represented by formula 1 or its hydrate thereof in crystalline or crystal-like form. | 10-20-2011 |
20110251152 | NUCLEOSIDE PHOSPHORAMIDATES - Disclosed herein are nucleoside phosphoramidates and their use as agents for treating viral diseases. These compounds are inhibitors of RNA-dependent RNA viral replication and are useful as inhibitors of HCV NS5B polymerase, as inhibitors of HCV replication and for treatment of hepatitis C infection in mammals. | 10-13-2011 |
20110245484 | STEREOSELECTIVE SYNTHESIS OF PHOSPHORUS CONTAINING ACTIVES - Disclosed herein are phosphorus-containing actives, their use as actives for treating diseases, and a stereoselective process for preparing the same. Also disclosed herein are useful synthetic intermediates and processes for preparing the same. | 10-06-2011 |
20110038833 | MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES - The disclosed invention provides compositions and methods of treating a Flaviviridae infection, including hepatitis C virus, West Nile Virus, yellow fever virus, and a rhinovirus infection in a host, including animals, and especially humans, using a (2′R)-2′-deoxy-2′-fluoro-2′-C-methyl nucleosides, or a pharmaceutically acceptable salt or prodrug thereof. | 02-17-2011 |
20110021454 | MODIFIED 4`-NUCLEOSIDES AS ANTIVIRAL AGENTS - Compounds, methods and compositions for treating a host infected with human immunodeficiency virus and hepatitis B virus comprising administering an effective amount of a described 4′-C-substituted β-D- and β-L-nucleoside or a pharmaceutically acceptable salt or prodrug thereof, are provided. | 01-27-2011 |
20110015146 | NUCLEOSIDE PHOSPHORAMIDATES - A nucleoside compound having activity against hepatitis C virus is disclosed. | 01-20-2011 |
20100298257 | NUCLEOSIDE PHOSPHORAMIDATES - Disclosed herein are nucleoside phosphoramidates and their use as agents for treating viral diseases. These compounds are inhibitors of RNA-dependent 5 RNA viral replication and are useful as inhibitors of HCV NS5B polymerase, as inhibitors of HCV replication and for treatment of hepatitis C infection in mammals. | 11-25-2010 |
20100286083 | NUCLEOSIDE ANALOGS - A purified compound having activity against hepatitis C virus is disclosed. | 11-11-2010 |
20100279973 | SYNTHESIS OF PURINE NUCLEOSIDES - A process for preparing phosphoramidate prodrugs or cyclic phosphate prodrugs of nucleoside derivatives, which is a compound, its stereoisomers, salts (acid or basic addition salts), hydrates, solvates, or crystalline forms thereof. | 11-04-2010 |
20100234585 | PREPARATION OF ALKYL-SUBSTITUTED 2-DEOXY-2-FLUORO-D-RIBOFURANOSYL PYRIMIDINES AND PURINES AND THEIR DERIVATIVES - The present invention provides (i) a process for preparing a 2-deoxy-2-fluoro-2-methyl-D-ribonolactone derivative, (ii) conversion of the lactone to nucleosides with potent anti-HCV activity, and their analogues, and (iii) a method to prepare the anti-HCV nucleosides containing the 2-deoxy-2-fluoro-2-C-methyl-β-D-ribofuranosyl nucleosides from a preformed, preferably naturally-occurring, nucleoside. | 09-16-2010 |
20100221217 | THERAPEUTIC COMPOSITION - Embodiments disclosed in the present application relate to a composition that can include a hepatitis C viral polymerase inhibitor, or pharmaceutically acceptable salt or prodrug thereof and a hepatitis C viral protease inhibitor, or pharmaceutically acceptable salt or prodrug thereof. Additional embodiments disclosed relate to methods for treating a disease condition such as a hepatitis C virus infection, liver fibrosis and/or impaired liver function with a hepatitis C viral polymerase inhibitor, or pharmaceutically acceptable salt or prodrug thereof and a hepatitis C viral protease inhibitor, or pharmaceutically acceptable salt or prodrug thereof. | 09-02-2010 |
20100168052 | Treatment of EBV and KHSV Infection and Associated Abnormal Cellular Proliferation - A method and composition for the treatment, prevention and/or prophylaxis of a host, and in particular, a human, infected with Epstein-Barr virus (EBV), is provided that includes administering an effective amount of a 5-substituted uracil nucleoside or its pharmaceutically acceptable salt or prodrug, optionally in a pharmaceutically acceptable diluent or excipient. | 07-01-2010 |
20100081628 | NUCLEOSIDE CYCLICPHOSPHATES - Cyclic phosphate of nucleoside derivatives for the treatment of viral infections in mammals, which is a compound, its stereoisomers, salts (acid or basic addition salts), hydrates, solvates, or crystalline forms thereof, represented by the following structure: | 04-01-2010 |
20100016251 | NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS - Disclosed herein are phosphoramidate prodrugs of nucleoside derivatives for the treatment of viral infections in mammals, which is a compound, its stereoisomer, salt (acid or basic addition salt), hydrate, solvate, or crystalline form thereof, represented by the following structure: | 01-21-2010 |
20090318380 | 2',4'-SUBSTITUTED NUCLEOSIDES AS ANTIVIRAL AGENTS - Embodiments of the invention are to compounds, methods, and compositions for use in the treatment of viral infections. More specifically embodiments of the invention are 2′,4′-substituted nucleoside compounds useful for the treatment of viral infections, such as HIV, HCV, and HBV infections. | 12-24-2009 |
20090220950 | SIMULTANEOUS QUANTIFICATION OF NUCLEIC ACIDS IN DISEASED CELLS - Processes and methods for the simultaneous quantification of nucleic acids in diseased cells that are based on real-time PCR are provided. The real-time PCR protocol is an excellent tool for reliable quantification of in vitro drug screening and evaluation protocols to determine the efficacy of potential anti-viral agents. Quantification using these simultaneous PCR cycle threshold (Ct) detection techniques during one-step real-time RT-PCR (Applied Biosystems, CA) eliminates the variability resulting from quantification of end-point RT-PCR products. In addition, the mitochondrial toxicity assay is an added tool to assess potential side-effects for these chemotherapeutic agents. | 09-03-2009 |
20090176730 | N4-ACYLCYTOSINE NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS - The present invention is directed to a method and composition of treating or preventing viral infections, in particular, human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infections, in human patients or other animal hosts, comprising the administration of N.sup.4-acyl-2′,3′-dideoxy-5-fluorocytidine or N.sup.4-acyl-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine, and pharmaceutically acceptable salts, prodrugs, and other derivatives thereof. | 07-09-2009 |
20090099136 | DIOXOLANE THYMINE PHOSPHORAMIDATES AS ANTI-HIV AGENTS - Disclosed are dioxolane thymine phosphoramidate compounds, compositions, and methods for using dioxolane thymine phosphoramidate compounds and compositions to treat viral infections, such as HIV infections. | 04-16-2009 |
20090036666 | MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES - The disclosed invention provides compositions and methods of treating a Flaviviridae infection, including hepatitis C virus, West Nile Virus, yellow fever virus, and a rhinovirus infection in a host, including animals, and especially humans, using a (2′R)-2′-deoxy-2′-fluoro-2′-C-methyl nucleosides, or a pharmaceutically acceptable salt or prodrug thereof. | 02-05-2009 |
20090004135 | MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES - The disclosed invention provides compositions and methods of treating a Flaviviridae infection, including hepatitis C virus, West Nile Virus, yellow fever virus, and a rhinovirus infection in a host, including animals, and especially humans, using a (2′R)-2′-deoxy-2′-fluoro-2′-C-methyl nucleosides, or a pharmaceutically acceptable salt or prodrug thereof. | 01-01-2009 |
20080280846 | 2', 3'-DIDEOXYNUCLEOSIDE ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRIDAE INFECTIONS - A method for the treatment or prevention of Flaviviridae infections, in particular, hepatitis C virus infection, in a host, and in particular, a human, is provided that includes administering an effective amount of a β-L- or β-D-2′,3′-dideoxynucleoside or a pharmaceutically acceptable salt or prodrug thereof, optionally in a pharmaceutically acceptable diluent or excipient. | 11-13-2008 |
20080253995 | MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES - The disclosed invention provides compositions and methods of treating a Flaviviridae infection, including hepatitis C virus, West Nile Virus, yellow fever virus, and a rhinovirus infection in a host, including animals, and especially humans, using a (2′R)-2′-deoxy-2′-fluoro-2′-C-methyl nucleosides, or a pharmaceutically acceptable salt or prodrug thereof. | 10-16-2008 |